Scott Kerlin, PhD, MS, Kerlin & Associates Research & Karen Fernandes, RN, CPHQ, CPAA, AYR Consulting Group , DES Info Association
This page introduces visitors to our 50-year historic review of research focusing on the effects of human exposure to the synthetic female estrogen diethylstilbestrol (DES). It was prescribed to pregnant women in the U.S. between 1940 and into the 1970sto prevent miscarriage, premature labor, and related complications of pregnancy. Outside of pregnancy use, DES was prescribed to suppress lactation, as an “After Morning Pill” and as an estrogen treatment to reduce the adult height of tall girls.
DES is now known as an endocrine-disrupting chemical (EDC), one of a number of substances that interfere with the endocrine system to potentially cause cancer, birth defects, and a variety of developmental and psychological/psychiatric effects.
We have devoted our ongoing collaborative investigation of DES to the body of published and investigative research emphasizing the following areas. We recommend this directory as a starting point for you as you seek to learn more about DES:
(1) DES Timeline, from the French Association of Patients and Victims of Diethylstilbestrol
(2) DES Timeline: Diethylstilbestrol (DES) From Discovery to Today, Updated 2023, by Karen Fernandes, RN, CPHQ, CPAA
(3) DES Mothers and Daughters Research Trends
(4) DES and Breast Cancer Research
(6) Third and Fourth Generation DES Research Trends
(7) DES and Psychiatric, Neurological, and Psychologic Effects
(8) DES and Reproduction, Sexuality, Gender-related Behavior, Gender Identity and Sexual Orientation Research
(9) Directory: Published Literature on DES Multigenerational Research Trends 1939-2023
(10) Dr. Kerlin’s 30-year (1993-2023) study focused Research on DES Sons and Human Health Effects: Emphasis on Gender and Sexuality
(11) Dr. Kerlin’s ongoing research emphasis on Gender Identity, Gender Dysphoria, Transgender, and Non-binary Individuals